Neuroendocrine tumors are thought to arise from cells throughout the diffuse endocrine system. They comprise a broad family of tumors, the most common of which are carcinoid and pancreatic neuroendocrine tumors. Other neuroendocrine tumors include those arising
Search Results
Matthew H. Kulke, Al B. Benson III, Emily Bergsland, Jordan D. Berlin, Lawrence S. Blaszkowsky, Michael A. Choti, Orlo H. Clark, Gerard M. Doherty, James Eason, Lyska Emerson, Paul F. Engstrom, Whitney S. Goldner, Martin J. Heslin, Fouad Kandeel, Pamela L. Kunz, Boris W. Kuvshinoff II, Jeffrey F. Moley, Venu G. Pillarisetty, Leonard Saltz, David E. Schteingart, Manisha H. Shah, Stephen Shibata, Jonathan R. Strosberg, Jean-Nicolas Vauthey, Rebekah White, James C. Yao, Deborah A. Freedman-Cass, and Mary A. Dwyer
Matthew H. Kulke, Manisha H. Shah, Al B. Benson III, Emily Bergsland, Jordan D. Berlin, Lawrence S. Blaszkowsky, Lyska Emerson, Paul F. Engstrom, Paul Fanta, Thomas Giordano, Whitney S. Goldner, Thorvardur R. Halfdanarson, Martin J. Heslin, Fouad Kandeel, Pamela L. Kunz, Boris W. Kuvshinoff II, Christopher Lieu, Jeffrey F. Moley, Gitonga Munene, Venu G. Pillarisetty, Leonard Saltz, Julie Ann Sosa, Jonathan R. Strosberg, Jean-Nicolas Vauthey, Christopher Wolfgang, James C. Yao, Jennifer Burns, and Deborah Freedman-Cass
Neuroendocrine tumors (NETs) are thought to arise from cells throughout the diffuse endocrine system. They comprise a broad family of tumors, the most common of which are carcinoid tumors (most commonly arising in the lungs and bronchi [so-called bronchopulmonary
Bonnie S. Glisson and Cesar A. Moran
Large-cell neuroendocrine carcinoma (LCNEC) is one of the most challenging diseases to diagnose in the practice of diagnostic surgical pathology, and is consequently challenging for oncologists to determine the best treatment. The knowledge of a
Rahul Aggarwal, Tian Zhang, Eric J. Small, and Andrew J. Armstrong
and outcomes of NEPC Outline treatment options for patients with NEPC Neuroendocrine prostate cancer (NEPC) is a lethal form of prostate cancer, with most patients dying within 1 to 2 years of diagnosis. 1 , 2 Pure localized small cell carcinoma
Ariel Polish, Maxwell T. Vergo, and Mark Agulnik
unknown origin on the basis of a review Describe the diagnostic workup of NETs of unknown origin on the basis of a review Describe the treatment of NETs of unknown origin on the basis of a review Neuroendocrine tumors (NETs) are formed from cells of the
Diane L. Reidy-Lagunes
Well-differentiated neuroendocrine tumors (NETs) can be subdivided into carcinoid and pancreatic NETs (pancNETs). Although these tumors share many morphologic and clinical characteristics, carcinoid tumors seem to be far less sensitive to
Natalie B. Jones, Manisha H. Shah, and Mark Bloomston
Neuroendocrine tumors (NETs) are rare, with a rising incidence over the past few decades of 5 to 7 cases per 100,000. 1 , 2 Gastroenteropancreatic NETs have the second highest prevalence of all gastrointestinal cancers. Not surprisingly, the liver is the most
Matthew H. Kulke
Understanding of neuroendocrine tumors (NETs) has rapidly evolved over the past several years. With this new knowledge, diagnoses have increased over the past few decades. NETs are thought to arise from cells in the diffuse neuroendocrine system
Manisha H. Shah, Whitney S. Goldner, Thorvardur R. Halfdanarson, Emily Bergsland, Jordan D. Berlin, Daniel Halperin, Jennifer Chan, Matthew H. Kulke, Al B. Benson III, Lawrence S. Blaszkowsky, Jennifer Eads, Paul F. Engstrom, Paul Fanta, Thomas Giordano, Jin He, Martin J. Heslin, Gregory P. Kalemkerian, Fouad Kandeel, Sajid A. Khan, Wajih Zaheer Kidwai, Pamela L. Kunz, Boris W. Kuvshinoff II, Christopher Lieu, Venu G. Pillarisetty, Leonard Saltz, Julie Ann Sosa, Jonathan R. Strosberg, Craig A. Sussman, Nikolaos A. Trikalinos, Nataliya A. Uboha, Jonathan Whisenant, Terence Wong, James C. Yao, Jennifer L. Burns, Ndiya Ogba, and Griselda Zuccarino-Catania
10, 2018; Expiration date: June 10, 2019 Learning Objectives: Upon completion of this activity, participants will be able to: Integrate into professional practice the updates to the NCCN Guidelines for Neuroendocrine and Adrenal Tumors Describe the
Julie Hallet, Calvin Law, Simron Singh, Alyson Mahar, Sten Myrehaug, Victoria Zuk, Haoyu Zhao, Wing Chan, Angela Assal, and Natalie Coburn
Background With increasing incidence worldwide and prolonged survival in the presence of active cancer because of unique tumor biology, neuroendocrine tumors (NETs) are now more prevalent than pancreatic, esophageal, and gastric cancers
